Mercaptopurin Silver

Mercaptopurine, the active ingredient in Mercaptopurin Silver, is a purine analog antimetabolite presented as an oral formulation for oral use. It is employed in the treatment of certain leukemias and inflammatory bowel diseases in adult and pediatric patients. GNH USA supplies Mercaptopurin Silver as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Mercaptopurin Silver is used as a purine‑analog antimetabolite in several hematologic and gastrointestinal disorders. - Acute lymphoblastic leukemia: helps achieve remission by targeting rapidly dividing lymphoblasts. - Chronic lymphocytic leukemia: contributes to disease control through inhibition of malignant B‑cell proliferation. - Inflammatory bowel disease (Crohn's disease, ulcerative colitis): reduces intestinal inflammation and maintains remission in patients with moderate to severe disease.

Mercaptopurin Silver may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Vomiting: occasional episodes after dosing. - Decreased appetite: reduced food intake. - Fatigue: feeling of tiredness or low energy.

Serious or Rare Side Effects: - Bone marrow suppression: can lead to anemia, neutropenia, or thrombocytopenia. - Severe infections: opportunistic infections due to immunosuppression. - Liver toxicity: elevated transaminases or hepatitis.

When using Mercaptopurin Silver, clinicians should observe several safety measures. - Monitor blood counts: regular CBC to detect marrow suppression early. - Assess liver function: periodic LFTs to identify hepatotoxicity. - Avoid use in pregnancy unless essential: drug is classified as Category D. - Adjust dose in renal impairment: consider reduced dosing in patients with decreased clearance. - Store below 25°C: keep in the original pack, protect from moisture.

Mercaptopurin Silver interacts with several medicines that can alter its safety or efficacy.

Major Interactions (Avoid): - Allopurinol: increases mercaptopurine toxicity and may cause severe myelosuppression. - Azathioprine: additive bone‑marrow suppression when used together. - Warfarin: potentiates anticoagulant effect, raising bleeding risk.

Moderate Interactions (Monitor Closely): - Methotrexate: combined use may enhance myelosuppression; monitor blood counts closely. - Trimethoprim‑sulfamethoxazole: can increase risk of bone‑marrow suppression; adjust therapy as needed.